H3K4me3 and H3K36me2 histone demethylase KDM2B is an epigenetic regulatory factor involved in cell proliferation in numerous cells including breast cancer cells, however, the regulatory mechanism of KDM2B in cell proliferation of breast cancer cells, specifically in triple negative breast cancer (TNBC), remains largely unknown. In this study, we showed that higher expression level of KDM2B was associated with poor prognosis in TNBC. Using cell proliferation assay, we found that KDM2B promoted TNBC cell proliferation by suppressing the transcription of the cell cycle inhibitors p15
associated with several types of cancers including breast cancer [2] . p16 INK4A has been shown to work in concert with BRCA1 to control mammary tumorigenesis [6] , and it is highly expressed in breast cancer cells with an estrogen receptor negative (ER−), progesterone receptor negative (PR−), and human epidermal growth factor receptor 2 negative (HER2−) phenotype, also known as triple negative breast cancer (TNBC) [7] . Thus, p16 INK4A plays an important role in the poor prognosis of TNBC [7] . p57 KIP2 is a cyclin-dependent kinase inhibitor belonging to the CIP/KIP family, which includes p21 Cip1/Waf1 and p27 Kip1 [8] . It is also an important regulator of the G1 phase of the cell cycle [9, 10] . In breast cancer, it has been reported that p57 KIP2 is down-regulated by DNA methylation of the promoter region [11] . Thus, transcriptional regulation of p15 KIP2 transcription, which is different from observations in leukemia and MEF cells. The chromatin immunoprecipitation (ChIP) assay indicated that KDM2B was recruited to the promoter site of the aforementioned genes and thereby reduced the H3K4me3 and H3K36me2 levels to suppress transcription. Silencing p15 INK4B , p16 INK4A , and p57 KIP2 in KDM2B-knockdown TNBC cells was capable of rescuing the promoter effect of KDM2B on cell proliferation. Thus, our study reveals a novel regulatory mechanism for TNBC cell proliferation that is mediated by KDM2B.
Materials and Methods

Breast cancer integrative platform database analysis
The prognostic value of the KDM2B gene in breast cancer was analyzed using the Breast Cancer Integrative Platform (BCIP) database (http://www.omicsnet.org/bcancer/database), which integrates gene expression data and breast cancer clinical data. The association of KDM2B expression levels with disease specific survival (DS) was analyzed in all breast cancer types, including TNBC and non-TNBC samples. Patient samples were split into two groups, namely, high and low KDM2B expression level, and compared using a BCIP survival plot. The hazard ratio was calculated with 95% confidence interval and log rank P value. We selected P < 0.05 as a threshold.
ShRNA, siRNA, and anitbodies
The lentivirus shRNA KDM2B-knockdown constructs and the siRNA of p15
INK4B
, p16
INK4A
, and p57 KIP2 were purchased from TranSheepBio (Shanghai, China). The sequences were shown in Table 1 . The negative control siRNAs (si-NC) and shRNA (NC) were provided by TranSheepBio. The sequences were also shown in Table 1 .
α-p16 INK4A (#ab108349), and α-p57 KIP2 (#ab133531) were purchased from Abcam (Cambridge, UK). Antibodies against α-GAPDH (#MA5-15738) and α-Flag (#MA1-91878) were purchased from Invitrogen (Carlsbad, USA). Antibodies against p21 CIP1 (#AP021) and p27
KIP1
(#AP027) were purchased from Beyotime (Shanghai, China). Antibodies against α-H3K4me3 (#ab8580) and α-H3K36me2 (#ab9049) were also purchased from Abcam. Anti-α-KDM2B was provided by Prof. Xudong Wu from Tianjin Medical University (Tianjin, China) and employed as previously reported [18] .
Generation of a stable cell line
The stable cell line Hs578t overexpressing KDM2B, and stable cell lines SUM159PT and MDA-MB-231 with KDM2B knockdown were established by lentivirus infection [16] . The shRNA sequences were also shown in Table 1 . Positive cells were screened by using G418 Sulfate (Invitrogen, #11811031 and puromycin #A1113803) for 2 weeks. KDM2B overexpression level and knockdown efficiency were analyzed by western blot analysis.
Cell proliferation
Cell proliferation was determined using the Cell Counting Kit-8 (CCK-8; Beyotime). The absorbance at 450 nm was measured using the Glomax Multi detection system (Promega, Madison, USA). The Colony formation assay and cell cycle assay were perfomed as previously reported [19] . In Colony formation assay, after WrightGiemsa staining, the number of colonies was counted, and the stain was subsequently dissolved in 100 μl of 33% acetic acid and the absorbence was measured at 570 nm. In cell cycle assay, the samples were analyzed with a BD LSRFortessa FACScan flow cytometer (BD Biosciences, Franklin Lakes, USA) and BD FACSDiva software. In Table 1 . Sequence of shRNA and siRNA used in this study
EdU incorporation assay, DNA synthesis was measured using the Click-iT ® EdU Flow Cytometry Assay Kits (Invitrogen).
ChIP assay
ChIP assays were performed essentially as previously described [20] . DNA that underwent ChIP was analyzed by quantitative PCR (qPCR), and data were presented as a percentage of the input. Primers used in the ChIP assay are listed in Supplementary Table S1 .
Statistical analysis
SPSS version 17.0 software was used for statistical analysis. Results are expressed as the mean ± standard deviation (SD). Student's t-test was used to estimate significant differences between groups. In all experiments, P < 0.05 was considered statistically significant.
Results
KDM2B promotes cell proliferation in breast cancer cells
To confirm the involvement of KDM2B in breast cancer cells, the association between KDM2B expression and DS was analyzed in 1980 cases in all types of breast cancer, including 319 cases TNBC and 1661 cases non-TNBC, using the BCIP database. It was found that high KDM2B expression level was positively correlated with poor prognosis in breast cancer patients ( Supplementary Fig. S1A ).
Interestingly, further analysis showed that high KDM2B expression levels were closely associated with low survival rates in TNBC patients ( Supplementary Fig. S1B ), rather than in non-TNBC patients (Supplementary Fig. S1C ). These results raised the possibility that KDM2B may play important roles in and act as a general biomarker for the poor TNBC prognosis. Considering the negative association between KDM2B expression level and survival rate in TNBC, we further investigated the role of KDM2B in TNBC cell proliferation. The expressions of KDM2B were examined in a panel of breast cancer cell lines, and several cell lines were selected to establish KDM2B-overexpresing or KDM2B-knockdown stable cell lines. It was found that KDM2B was expressed in most breast cancer cell lines (including TNBC and non-TNBC cell lines), while low expression levels were observed in MCF10A and Hs578t cell lines ( Supplementary Fig. S2A,D) . There were no significant differences in the expression levels between TNBC and non-TNBC cell lines. To explore the function of KDM2B in TNBC, a KDM2B-overexpressing stable cell line was established in Hs578t cells and two KDM2B-knockdown stable cell lines were established in SUM159PT and MDA-MB-231 cells. Overexpression level of KDM2B was characterized by western blot analysis ( Supplementary Fig. S2B ). KDM2B knockdown efficiency was analyzed by both western blot analysis ( Supplementary  Fig. S2C ) and q-PCR ( Supplementary Fig. S2E,F) .
In addition, both the stable KDM2B-overexpressing and KDM2B-knockdown cells were counted for 4 consecutive days using the CCK-8 assay. Increased KDM2B expression was found to significantly promote cell proliferation (Fig. 1A) , while silencing KDM2B suppressed cell proliferation (Fig. 1B,C) . To further evaluate the long-term impact on cell proliferation, the colony formation assay was performed. Compared with their respective controls, the number of colonies increased in cells overexpressing KDM2B (Fig. 1D,F) , whereas decreased in KDM2B-knockdown cells (Fig. 1E,G,H) . To better understand the role of KDM2B in TNBC proliferation, the cell cycle was analyzed by flow cytometry. Cells overexpressing KDM2B showed a decrease in the G0/G1 phase population, with a corresponding increase in the S and G2/M phase populations ( Fig. 2A) . In contrast, silencing KDM2B increased the G0/G1 phase population, with a corresponding decrease in the S and G2/M phase populations (Fig. 2B,C) . To further demonstrate the potential role of KDM2B in accelerating cell cycle progression, EdU incorporation assay was performed. It was found that the percentage of EdU positive cells was reduced in KDM2B-knockdown SUM159PT and MDA-MB-231 cells (Supplementary Fig. S3A ), suggesting that KDM2B regulates breast cancer cell cycle progression by releasing breast cancer cells from the G0/G1 phase into the S and G2/M phases. We also analyzed the apoptosis in KDM2B-knockdown SUM159PT and MDA-MB-231 cells, and found that KDM2B had no effect on breast cancer cell apoptosis ( Supplementary Fig. S3B) .
In order to compare the KDM2B effects on proliferation in TNBC, we also examine the effect of KDM2B in 293 T cell. We established a stable KDM2B-knockdown 293 T cell line and analyzed the knockdown efficiency by western blot analysis ( Supplementary Fig. S4A ). Both CCK-8 assay and cell cycle analysis suggested that KDM2B had less effect on the proliferation of 293 T cells than on the proliferation of breast cancer cells ( Supplementary Fig. S4B,C) .
All the above results indicate that KDM2B is a potential regulator for promoting the proliferation in TNBC.
KDM2B promotes breast cancer cell proliferation by repressing p15 INK4B , p16 INK4A , and p57 KIP2 transcription
To explore the regulatory mechanism of KDM2B in TNBC cell proliferation, we examined a panel of proliferation-related gene transcription level in the stable KDM2B-knockdown SUM159PT and MBA-MD-231 cell lines. Interestingly, the INK4 family members of cyclin-dependent kinase CDK4 and CDK6 inhibitors, p15 INK4B and p16 INK4A , which arrest the cell cycle in early G1 phase [2] [3] [4] , were significantly upregulated following KDM2B silencing (Fig. 3A,B) .
As a cyclin-dependent kinase inhibitor belonging to the CIP/KIP family [8] , which is also an important regulator of the G1 phase [9, 10] , p57 KIP2 was also significantly upregulated following silencing of KDM2B (Fig. 3A,B) . In addition, the transcription level of the cyclin-dependent kinase CDK4 was slightly reduced, while that of CDK6 showed no alteration (Fig. 3A,B) . Considering the inhibitory effect mediated by cyclin-dependent kinase inhibitors through protein interaction, the slight change in the transcription of CDK4 and CDK6 may not impact the proliferation function mediated by the cyclin-dependent kinase inhibitors p15 INK4B , p16
INK4A
, and p57
KIP2
. In the stable cell line Hs578t overexpressing KDM2B, the transcription levels of p15
INK4B
INK4A
, and p57 KIP2 were found to be largely inhibited (Fig. 3C) . Consistent with qPCR data, the protein expression levels of these genes were also reduced in cells overexpressing KDM2B and increased in KDM2B-knockdown breast cancer cells (Fig. 3D) . However, we also analyzed the transcription levels of p15 INK4B , p16
, and p57 KIP2 in KDM2B- Figure 2 . Silencing KDM2B increases the G0/G1 phase population and decreases in the S and G2/M phase populations in breast cancer cells Cell cycle distribution was examined by flow cytometry and the percentage of cells in G0/G1, S, and G2/M phase were analyzed in the stable Hs578t cell line overexpressing KDM2B (A), and in stable KDM2B-knockdown cell lines of SUM159PT (B) and MDA-MB-231 (C). Data are presented as the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
amplicon P1 and P2 regions of the p57 KIP2 promoter ( Supplementary   Fig. S5F ). The H3K4me3 and H3K36me2 methylation levels were subsequently found to be low in the KDM2B-associated regions ( Supplementary Fig. S5B,D,F) , suggesting that the KDM2B transcription repression effect is associated with histone demethylase activity. To further confirm the KDM2B repression effect on these associated regions, the ChIP assay was employed in the stable KDM2B-knockdown SUM159PT cell line. Compared with the NC, KDM2B silencing was found to reduce the occupancy of KDM2B in aforementioned regions, while increase the H3K4me3 and H3K36me2 levels in the corresponding KDM2B-associated regions without changing the total H3 levels (Fig. 4B,D,F , and p57 KIP2 protein levels in the stable Hs578t cell line overexpressing KDM2B and in the stable KDM2B-knockdown SUM159PT and MBA-MD-231 cell lines (D), and the p21 CIP1 and p27 KIP1 protein levels in the stable KDM2B-knockdown SUM159PT cell lines (E). Data are presented as the mean ± SD of three independent experiments. ***P < 0.001.
